Renal and related cardiovascular effects of conventional and COX-2-specific NSAIDs and non-NSAID analgesics

Andrew Whelton

Research output: Contribution to journalArticle

Abstract

On a daily basis it appears that as many as one in five adults in the United States may consume an analgesic compound either on a prescription basis or by over-the-counter (OTC) purchase. This high profile of intermittent or repetitive analgesic use appears to be relatively similar throughout the developed world. Although analgesics generally have a good renal safety profile, the nonsteroidal anti-inflammatory drug (NSAID) analgesics may produce mild renal side effects, such as the generation of peripheral edema in up to 5% of the general population. Other more serious renal and related cardiovascular side effects tend to be more apparent in lesser numbers of clinically "at risk" NSAID analgesic users. In contrast, non-NSAID analgesics, such as paracetamol or tramadol, have essentially no renal or related cardiovascular side effects when used at recommended dosing schedules. This review characterizes the renal syndromes associated with the use of NSAID analgesics, identifies the risks inherent in the use of these compounds in treated patients with hypertension and congestive heart failure, summarizes the early comparable data available for the new COX-2-specific inhibitors, and profiles the scant acute and long-term clinical concerns attendant with the use of non-NSAID nonnarcotic analgesics. It is important that healthcare providers and practitioners are aware of the relative renal risks of different analgesics and that they use this knowledge to counsel the analgesic-consuming population appropriately.

Original languageEnglish (US)
Pages (from-to)63-74
Number of pages12
JournalAmerican Journal of Therapeutics
Volume7
Issue number2
StatePublished - 2000

Fingerprint

Non-Steroidal Anti-Inflammatory Agents
Analgesics
Kidney
Pharmaceutical Preparations
Non-Narcotic Analgesics
Tramadol
Cyclooxygenase 2 Inhibitors
Acetaminophen
Drug Users
Health Personnel
Population
Prescriptions
Edema
Appointments and Schedules
Anti-Inflammatory Agents
Heart Failure
Hypertension
Safety

Keywords

  • Acetaminophen
  • Analgesic
  • Hypertension
  • Nephrotoxicity
  • NSAID
  • Paracetamol

ASJC Scopus subject areas

  • Pharmacology

Cite this

Renal and related cardiovascular effects of conventional and COX-2-specific NSAIDs and non-NSAID analgesics. / Whelton, Andrew.

In: American Journal of Therapeutics, Vol. 7, No. 2, 2000, p. 63-74.

Research output: Contribution to journalArticle

@article{1a910b402ce34f549104908e9e7994e3,
title = "Renal and related cardiovascular effects of conventional and COX-2-specific NSAIDs and non-NSAID analgesics",
abstract = "On a daily basis it appears that as many as one in five adults in the United States may consume an analgesic compound either on a prescription basis or by over-the-counter (OTC) purchase. This high profile of intermittent or repetitive analgesic use appears to be relatively similar throughout the developed world. Although analgesics generally have a good renal safety profile, the nonsteroidal anti-inflammatory drug (NSAID) analgesics may produce mild renal side effects, such as the generation of peripheral edema in up to 5{\%} of the general population. Other more serious renal and related cardiovascular side effects tend to be more apparent in lesser numbers of clinically {"}at risk{"} NSAID analgesic users. In contrast, non-NSAID analgesics, such as paracetamol or tramadol, have essentially no renal or related cardiovascular side effects when used at recommended dosing schedules. This review characterizes the renal syndromes associated with the use of NSAID analgesics, identifies the risks inherent in the use of these compounds in treated patients with hypertension and congestive heart failure, summarizes the early comparable data available for the new COX-2-specific inhibitors, and profiles the scant acute and long-term clinical concerns attendant with the use of non-NSAID nonnarcotic analgesics. It is important that healthcare providers and practitioners are aware of the relative renal risks of different analgesics and that they use this knowledge to counsel the analgesic-consuming population appropriately.",
keywords = "Acetaminophen, Analgesic, Hypertension, Nephrotoxicity, NSAID, Paracetamol",
author = "Andrew Whelton",
year = "2000",
language = "English (US)",
volume = "7",
pages = "63--74",
journal = "American Journal of Therapeutics",
issn = "1075-2765",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Renal and related cardiovascular effects of conventional and COX-2-specific NSAIDs and non-NSAID analgesics

AU - Whelton, Andrew

PY - 2000

Y1 - 2000

N2 - On a daily basis it appears that as many as one in five adults in the United States may consume an analgesic compound either on a prescription basis or by over-the-counter (OTC) purchase. This high profile of intermittent or repetitive analgesic use appears to be relatively similar throughout the developed world. Although analgesics generally have a good renal safety profile, the nonsteroidal anti-inflammatory drug (NSAID) analgesics may produce mild renal side effects, such as the generation of peripheral edema in up to 5% of the general population. Other more serious renal and related cardiovascular side effects tend to be more apparent in lesser numbers of clinically "at risk" NSAID analgesic users. In contrast, non-NSAID analgesics, such as paracetamol or tramadol, have essentially no renal or related cardiovascular side effects when used at recommended dosing schedules. This review characterizes the renal syndromes associated with the use of NSAID analgesics, identifies the risks inherent in the use of these compounds in treated patients with hypertension and congestive heart failure, summarizes the early comparable data available for the new COX-2-specific inhibitors, and profiles the scant acute and long-term clinical concerns attendant with the use of non-NSAID nonnarcotic analgesics. It is important that healthcare providers and practitioners are aware of the relative renal risks of different analgesics and that they use this knowledge to counsel the analgesic-consuming population appropriately.

AB - On a daily basis it appears that as many as one in five adults in the United States may consume an analgesic compound either on a prescription basis or by over-the-counter (OTC) purchase. This high profile of intermittent or repetitive analgesic use appears to be relatively similar throughout the developed world. Although analgesics generally have a good renal safety profile, the nonsteroidal anti-inflammatory drug (NSAID) analgesics may produce mild renal side effects, such as the generation of peripheral edema in up to 5% of the general population. Other more serious renal and related cardiovascular side effects tend to be more apparent in lesser numbers of clinically "at risk" NSAID analgesic users. In contrast, non-NSAID analgesics, such as paracetamol or tramadol, have essentially no renal or related cardiovascular side effects when used at recommended dosing schedules. This review characterizes the renal syndromes associated with the use of NSAID analgesics, identifies the risks inherent in the use of these compounds in treated patients with hypertension and congestive heart failure, summarizes the early comparable data available for the new COX-2-specific inhibitors, and profiles the scant acute and long-term clinical concerns attendant with the use of non-NSAID nonnarcotic analgesics. It is important that healthcare providers and practitioners are aware of the relative renal risks of different analgesics and that they use this knowledge to counsel the analgesic-consuming population appropriately.

KW - Acetaminophen

KW - Analgesic

KW - Hypertension

KW - Nephrotoxicity

KW - NSAID

KW - Paracetamol

UR - http://www.scopus.com/inward/record.url?scp=0034158368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034158368&partnerID=8YFLogxK

M3 - Article

C2 - 11319575

AN - SCOPUS:0034158368

VL - 7

SP - 63

EP - 74

JO - American Journal of Therapeutics

JF - American Journal of Therapeutics

SN - 1075-2765

IS - 2

ER -